tiprankstipranks
Advertisement
Advertisement
Edwards Lifesciences announces new data on EVOQUE TTVR system
PremiumThe FlyEdwards Lifesciences announces new data on EVOQUE TTVR system
16d ago
Oppenheimer downgrades AtriCure on new competition from Edwards
Premium
The Fly
Oppenheimer downgrades AtriCure on new competition from Edwards
2M ago
Early notable gainers among liquid option names on February 17th
Premium
The Fly
Early notable gainers among liquid option names on February 17th
2M ago
Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside
PremiumRatingsEdwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside
2M ago
Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating
Premium
Ratings
Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating
2M ago
Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile
Premium
Ratings
Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile
2M ago
Edwards Lifesciences reports Q4 adjusted EPS 58c, consensus 62c
PremiumThe FlyEdwards Lifesciences reports Q4 adjusted EPS 58c, consensus 62c
2M ago
Edwards Lifesciences sees Q1 adjusted EPS 70c-76c, consensus 69c
Premium
The Fly
Edwards Lifesciences sees Q1 adjusted EPS 70c-76c, consensus 69c
2M ago
Edwards Lifesciences backs FY26 EPS view $2.90-$3.05, consensus $2.91
Premium
The Fly
Edwards Lifesciences backs FY26 EPS view $2.90-$3.05, consensus $2.91
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100